Journal of Neuro-Oncology

, Volume 136, Issue 2, pp 273–280 | Cite as

Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit

  • William Sage
  • Mathew Guilfoyle
  • Catriona Luney
  • Adam Young
  • Rohitashwa Sinha
  • Donatella Sgubin
  • Joseph H. McAbee
  • Ruichong Ma
  • Sarah Jefferies
  • Rajesh Jena
  • Fiona Harris
  • Kieren Allinson
  • Tomasz Matys
  • Wendi Qian
  • Thomas Santarius
  • Stephen Price
  • Colin WattsEmail author
Open Access
Clinical Study


Grade IV glioma is the most common and aggressive primary brain tumour. Gross total resection with 5-aminolevulinic acid (5-ALA) guided surgery combined with local chemotherapy (carmustine wafers) is an attractive treatment strategy in these patients. No previous studies have examined the benefit carmustine wafers in a treatment programme of 5-ALA guided resection followed by a temozolomide-based chemoradiotherapy protocol. The objective of this study was to examine the benefit of carmustine wafers on survival in patients undergoing 5-ALA guided resection. A retrospective cohort study of 260 patients who underwent 5-ALA resection of confirmed WHO 2007 Grade IV glioma between July 2009 and December 2014. Survival curves were calculated using the Kaplan–Meier method from surgery. The log-rank test was used to compare survival curves between groups. Cox regression was performed to identify variables predicting survival. A propensity score matched analysis was used to compare survival between patients who did and did not receive carmustine wafers while controlling for baseline characteristics. Propensity matched analysis showed no significant survival benefit of insertion of carmustine wafers over 5-ALA resection alone (HR 0.97 [0.68–1.26], p = 0.836). There was a trend to higher incidence of wound infection in those who received carmustine wafers (15.4 vs. 7.1%, p = 0.064). The Cox regression analysis showed that intraoperative residual fluorescent tumour and residual enhancing tumour on post-operative MRI were significantly predictive of reduced survival. Carmustine wafers have no added benefit following 5-ALA guided resection. Residual fluorescence and residual enhancing disease following resection have a negative impact on survival.


Neurosurgery Glioma 5-Aminolevulinic acid Carmustine 


WHO Grade IV glioma is the most common and aggressive primary brain tumour and presents amongst the most formidable challenges of any cancer. Each year in the UK ~ 4300 new cases of brain or central nervous system (CNS) cancers are diagnosed, around 7 per 100,000 population. Although brain tumours account for < 2% of all primary tumours they are responsible for 7% of the years of life lost from cancer before age 70 (ONS 2006 Series MB1 No. 34). If the burden of disease is considered in terms of the average years of life lost per patient, brain tumours are one of the most lethal cancers with over 20 years of life lost [1].

Surgery remains a mainstay of treatment and is essential in establishing a diagnosis. As surgical techniques have improved, the importance of obtaining a gross total resection is increasingly recognized and is being incorporated into European guidelines [2, 3]. Prospective cohort data suggest that radical resection, defined by the absence of post-operative contrast enhancing disease, improves survival (over 9 months) [4], that gross total resection (GTR) but not incomplete resection of glioblastoma prolongs survival (6 months) in the era of radiochemotherapy [5] and also that multiple resections for patients with glioblastoma can prolong survival [6].

Complete resection of contrast enhancing disease is only achieved in a minority of patients because identifying the margin between tumour and adjacent brain intraoperatively is frequently challenging. 5-aminolevulinic acid (5-ALA) is a heme precursor that after oral administration results in accumulation of porphyrins in epithelial and neoplastic cells, including malignant glioma. Under ultraviolet light from an operating microscope tumour tissue is distinctly fluorescent compared with surrounding white matter and provides the surgeon with real-time intraoperative guidance during resection [7]. A phase III randomised controlled trial has shown that 5-ALA guided resection of malignant glioma is associated with a significant increase in the proportion of patients where complete resection of enhancing tumour is achieved and improved progression-free survival at 6 months [8].

Local chemotherapy with biodegradable carmustine impregnated wafers inserted into the surgical resection cavity is an attractive strategy to directly deliver an active agent into the brain interstitium and circumvent the limited bioavailability and the adverse effects associated with systemic administration [9]. Although two randomised trials pointed towards a treatment effect of carmustine wafers for newly diagnosed grade IV glioma [10, 11], these were shortly followed by clear evidence of significantly improved survival with combined radiotherapy and systemic temozolomide. In this context, together with improved surgical resection strategies, the efficacy of carmustine wafers remains unproven.

The objective of this study was to examine the additional benefit of carmustine wafers on survival in patients undergoing 5-ALA guided tumour resection and factors correlated with survival.


Data collection

Since July 2009 all patients who receive 5-ALA fluorescence guided resection and/or carmustine wafers (Gliadel) implants have been prospectively recorded at our unit. From this database we selected all patients who underwent primary resection of a radiologically suspected malignant glioma and in whom the histopathological analysis subsequently confirmed a WHO 2007 grade IV glioma, operated on between July 2009 and December 2014.

Electronic health records were accessed to retrieve additional data regarding the surgical procedure, pathological findings, and adjuvant chemo- and radiotherapy the patient received. Our unit policy is to obtain post-operative contrast enhanced cerebral magnetic resonance imaging (MRI) within 72 h from surgery. The neuroradiologists’ reports were reviewed for each patient in the cohort to determine whether any contrast enhancing tumour remained following surgery.

The location of each tumour was determined following review of relevant neuroradiology reports, operative notes, and preoperative stealth MRIs. In the event that a tumour extended into multiple regions (e.g. parieto-occipital), it was counted in the total for both involved regions. Tumour size was defined by measuring the maximum axial dimension on preoperative scans. Measurements were corroborated with neuroradiology reports, whenever possible, and placed into RTOG size groups.

The decision of intention to insert carmustine wafers was made pre-operatively and then confirmed once the intraoperative frozen section indicated a high-grade glioma and there were no contraindications such as a wide opening of the lateral ventricle. Between four and eight wafers were inserted.

Post-operative oncology treatment, if received, was classified as either palliative: radiotherapy (typically 30 Gy in six fractions), or radical radiotherapy (60 Gy in 30 fractions), or radical chemo-radiotherapy i.e. radiotherapy combined with concomitant and/or adjuvant temozolomide as per the Stupp protocol [4].

Current status of patients and dates of death were ascertained through the NHS national tracing service on 01 January 2017 i.e. a minimum of 2 years after diagnosis. The project was registered and approved with the local audit department prior to data collection (local audit number PRN 4507).

IDH1 and IDH2 mutation analysis and MGMT methylation analysis

Immunohistochemistry for the protein product of mutant IDH1 R132H was performed on deparaffinised sections after heat-induced antigen retrieval. In appropriate cases that did not have the common mutation, tumour samples were submitted for next-generation sequencing to look for rarer IDH1 mutations on exon 4, codon 132, and mutations of IDH2 on exon 4, codon 172. To determine MGMT promoter methylation status, tumour DNA was extracted and bisulphite-converted. The MGMT promoter methylation was determined by pyrosequencing of four CpG sites (CpGs 76–79) in exon 1 of the MGMT gene using the CE-Marked Therascreen MGMT Pyro Kit on a Pyromark Q24 System (Qiagen). A cut-off of 10% methylation for the four CpG sites is used to assign a glioma as methylated or unmethylated based on published data [12, 13, 14].

Statistical analysis

The effect of 5-ALA guidance on extent of resection was measured as whether there was residual enhancing tumour on early post-operative MRI. Comparison was made using the standard chi-squared test between patients with or without 5-ALA guided resection.

Overall survival curves were calculated using the Kaplan–Meier method from the date of surgery until date of death from all causes. The log-rank test was used to compare survival curves between carmustine versus no carmustine. Cox proportional hazards regression was performed to investigate independent factors predicting survival.

To compare survival between patients who did and did not receive carmustine wafers while controlling for differences in their baseline characteristics a propensity score matched analysis was also conducted [15]. The propensity score was calculated with a logistic regression of age, sex, tumour size, presence of residual (5-ALA) fluorescence at the end of resection, and whether the lateral ventricle had been opened during the procedure. Control (i.e. no carmustine wafers) patients were then matched to patients who received carmustine wafers with an optimal matching procedure and caliper width of 0.1, without replacement.

The independent effect on survival of variables such as carmustine wafers and residual enhancement on post-operative MRI was further estimated using standardised inverse probability weighting to adjust the respective survival curves. The weighting was calculated as the actual probability of group assignment divided by the predicted group assignment based on a logistic regression of other pre- and post-operative variables.

All analysis was carried out in R (v. 3.3.0; using the stats, survival, and MatchIt packages. Statistical significance level was set at p < 0.05.


5-ALA and carmustine wafers

A total of 260 patients underwent primary 5-ALA guided resection of a confirmed grade IV glioma between 2009 and 2014; 78 (30%) of these also received carmustine wafer implants. The age, sex, and pathology of patients in each group were similar. However, tumour size (RTOG classification), completeness of resection based on residual fluorescence and MRI, and the oncological treatment patients received following surgery was significantly different between the groups (Table 1). The variation in post-operative oncological management reflects the real-world nature of the patient cohort consistent with a surgical study. NICE guidelines permit RT/TMZ (Stupp protocol) for patients with PS 0–1 so post-operative changes may alter subsequent treatment. There was an association between tumour size and presence of residual enhancement on post-operative MRI (RTOG I: 32.4% vs. RTOG II: 45.5%, p = 0.044). In addition, there was a trend to higher incidence of wound infection requiring revision surgery in the patients who received carmustine wafers (12/78 [15.4%] vs. 13/182 [7.1%], p = 0.064).

Table 1

Details of the patient cohort


5-ALA; no wafers

5-ALA; with wafers






Age (years; median [IQR])

63 [10]

61 [14]

P = 0.07

Sex (% male)



P = 0.50

RTOG class (%)


P = 0.043











P = 0.240

















Residual disease (%)





P = 0.04




P = 0.10

Wound infection (%)



P = 0.06

Pathology (%)


P = 0.16

















Post-operative treatment (%)


P = 0.0009





 Palliative RT (30 Gy)




 Radical RT (60 Gy)




 Chemotherapy + RT (60 Gy)




 Repeat resection (%)



P = 0.25

5-ALA 5-aminolevulinic acid, RT radiotherapy, RTOG radiation therapy oncology group, GBM glioblastoma multiforme, GBMO GBM with oligodendroglial component, GBMP GBM with primitive neuroectodermal tumour (PNET) differentiation, GS gliosarcoma

Unadjusted comparison of survival between patients who received carmustine and those who did not, found 6 month survival was not significantly different (carmustine vs. no carmustine; 16.7 vs. 24.2%, p = 0.239). There was a significant difference at 12 months (35.9 vs. 54.4%, p = 0.009) but this did not persist at 24 months (78.2 vs. 82.4%, p = 0.338) and overall comparison of survival curves similarly found no significant difference (median 14.7 vs. 11.0 months; hazard ratio [95% CI] 0.81 [0.54–1.09], p = 0.13; Fig. 1a).

Fig. 1

Comparison of survival for patients treated with or without carmustine wafers. Kaplan–Meier survival curves for patients having 5-ALA guided resection without carmustine wafers (No CW) and 5-ALA resection with carmustine wafers (CW). a Unadjusted analysis of the two patient groups. b Groups matched for baseline covariates by propensity score (see text for details). c Survival curves adjusted for baseline covariates and post-operative treatment by inverse probability weighting. HR hazard ratio for the log-rank test

We then calculated a propensity score for the use of carmustine wafers for each patient based on pre-implantation factors comprising age, sex, tumour size, presence of residual fluorescent tumour, and whether the lateral ventricle was opened. This allowed 76 patients who received carmustine wafers to be matched to the same number of patients with similar pre-implantation features who did not receive carmustine wafers. Comparison of survival between these matched groups found no significant difference in overall survival (median 14.2 vs. 14.3 months; HR 1.10 [0.79–1.53], p = 0.59; Fig. 1b).

To examine the independent effects of both pre- and post-operative factors on survival a Cox proportional hazards regression model was constructed. Age, tumour size, residual intraoperative fluorescent tumour, residual enhancing tumour on early post-operative MRI, and adjuvant treatment were identified as significantly associated with survival, whereas use of carmustine wafers was not (Table 2).

Table 2

Cox-regression analysis (n = 248)



P value

Age (per year)



Sex (female vs. male)



Carmustine wafers














Pathology (vs. GBM)











MGMT methylation positive (n = 128)



IDH1 (n = 128)



Post-operative treatment (vs. none)


 Palliative RT (30 Gy)



 Radical RT (60 Gy)



 Chemotherapy + RT (60 Gy)


< 10 −10

 Repeat resection



Bold indicate P values of < 0.05

Abbreviations as in Table 1

Correspondingly, survival curves adjusted for both pre- and post-operative factors, namely age, sex, tumour size, residual fluorescence, residual enhancing tumour on MRI, and adjuvant treatment, using standardised inverse variance weighting were essentially indistinguishable between the group of patients who received carmustine wafers and those who did not (median 12.3 vs. 12.6 months; HR 1.12 [0.85–1.50], p = 0.44; Fig. 1c).

Residual tumour

The Cox regression analysis showed that both intraoperative residual fluorescent tumour and residual enhancing tumour on post-operative MRI were significantly predictive of reduced overall survival (Table 2). To further demonstrate this, survival curves for patients with or without residual enhancing tumour on MRI adjusted for age, sex, tumour size, insertion of carmustine wafers, and adjuvant therapy, were constructed and revealed significantly better survival for patients without residual tumour (median 13.5 vs. 10.5 months; HR 0.73 [0.56–0.95], p = 0.022; Fig. 2).

Fig. 2

Effect on Survival of Residual Enhancing Tumour on MRI. Kaplan–Meier survival curves, adjusted for baseline covariates and post-operative treatment, for patients with and without evidence of residual enhancing tumour on post-operative MRI within 72 h from surgery. HR hazard ratio for the log-rank test

Importantly, though the presence of residual 5-ALA fluorescence and residual contrast enhancement on early MRI were consistent in 154 (59.3%) of patients, in a substantial proportion 106 (40.7%) the intraoperative and post-operative assessment of residual disease differed (Table 3).

Table 3

Comparison of residual fluorescence with residual enhancement on MRI



Residual MRI enhancement



Residual 5-ALA fluorescence







MGMT and IDH-1 status

Routine clinical evaluation of MGMT methylation status and IDH-1/2 mutation were available for 226 (111 methylated) and 128 (10 mutated) patients, respectively. Surprisingly, MGMT methylation was not significantly associated with survival on univariate analysis (HR 1.06 [0.81–1.39]) and in the multivariable Cox model (Table 2).

For the ten patients with the IDH-1/2 mutation median survival was markedly longer than for the wildtype patients (median 24.1 vs. 12.6 months, log-rank test p = 0.067, likelihood ratio test p = 0.045). The borderline statistical significance presumably reflects the low number of patients with the mutation in this study.


This study has shown that implantation of carmustine wafers does not have an independent effect on survival in patients undergoing 5-ALA guided resection of glioblastoma. In contrast, extent of resection, as evidenced by residual 5-ALA fluorescence and/or residual contrast enhancement on MRI, was found to be an independent prognostic factor for overall survival.

Although the raw unadjusted analyses pointed to a potential benefit of carmustine wafers, when preoperative factors including age, size of tumour, and residual fluorescence, were appropriately controlled for there was no demonstrable effect on outcome. Additional adjustment for post-operative factors, including radiological residual tumour and adjuvant therapy, also did not reveal any benefit of carmustine wafers. Accordingly, the fully adjusted survival curves for patients who did and did not receive carmustine wafers were similar and, within the limits of this study, there did not appear to be a marginal effect of carmustine wafers that might emerge as statistically or clinically significant in a larger cohort. Moreover, carmustine wafers were associated with a tendency to a higher wound complications and infection.

While the implantation of carmustine wafers is an appealing approach to deliver high local concentrations of chemotherapy; they have been shown to provide only limited penetration and degrade over the course of 6–8 weeks [16]. With this pharmacokinetic profile, it may be the case that local carmustine are effective at the resection margins but have no impact on malignant cells penetrating beyond the enhancing disease evident on MRI.

The phase III randomised trial by Stummer and colleagues showed that 5-ALA guided resection nearly doubled the proportion of patients in whom a complete resection was achieved (65 vs. 36%) and this in turn was associated with a significant increase in progression-free survival at 6 months (41.0 vs. 21.1%) [8]. However, the study was designed and conducted prior to temozolomide emerging as the optimal post-surgical treatment of WHO grade IV glioma, and patients allocated to both 5-ALA and control groups received radiotherapy only as first line adjuvant therapy, with chemotherapy reserved until tumour recurrence. In the phase III trial of radiotherapy compared with combined radiotherapy and concomitant and adjuvant temozolomide by Stupp et al. there was a significant survival benefit in the chemotherapy arm (median 14.6 vs. 12.1 months) [17]. Moreover, a post-hoc analysis of the trial data suggested that the greatest benefit of the radiotherapy plus temozolomide regimen was in patients with greater tumour resection [8]. Together, these trials indicate that improved resection directly extends survival and enhances the treatment effect of radical chemo-radiotherapy. Both 5-ALA guided surgery and temozolomide based chemo-radiotherapy are being used increasingly in modern practice with a demonstrated increase in overall survival [18].

In contrast to the widespread adoption of fluorescence-guided surgery and temozolomide-based adjuvant therapy, the role of local chemotherapy in the form of implantable carmustine wafers has remained controversial. Two randomised controlled trials have assessed the efficacy of carmustine wafers inserted at primary surgery for suspected malignant glioma [10]. In the initial small study by Valtonnen et al. randomising 32 patients (27 confirmed as grade IV glioma) a significant survival benefit associated with carmustine wafers was observed. The subsequent phase III study by Westphal et al. enrolled 240 patients and showed an overall 2-month improvement in median survival but the difference between treatment groups for the subset of patients with grade IV glioma was not significant [11]. Moreover, in both trials post-operative treatment was again limited to radiotherapy alone until tumour recurrence. The inconclusive trial findings and the proven efficacy of combined radiotherapy and temozolomide has limited the routine adoption of carmustine wafers as a primary therapy. Nonetheless, a number of reports have detailed the outcomes of multimodal treatment with carmustine wafers followed by combined radiotherapy and temozolomide, and in general suggest longer median overall survival than observed in either the Stupp et al. or Westphal et al. RCTs [19]. However, such observational studies are inherently subject to selection bias. Further, since the introduction of technologies such as 5-ALA to maximise tumour resection, the added benefit of carmustine wafers has become increasingly unclear.

In our centre, 5-ALA guided tumour resection and radical chemoradiotherapy with temozolomide have been the standard of care since 2009. The proportion of patients in whom a complete resection was achieved under 5-ALA guidance was similar to that in the original RCT by Stummer et al. [8]. The overall outcomes in the present cohort are improved over historical data from our unit prior to the introduction of 5-ALA guided resection and temozolomide chemotherapy [20]. Currently we utilise 5-ALA routinely in patients where there is intent to resect tumour to its enhancing margin, if possible around the entire tumour or restricted to regions bordering non-eloquent brain. Intraoperatively, the resection of fluorescent tumour is judiciously assessed against the risk of neurological deficit, incorporating neurophysiological cortical and subcortical mapping and awake testing where appropriate [9]. Higher rates of complete resection with 5-ALA have been reported in other studies but these series are typically highly selected subgroups of patients in whom total resection is deemed possible at the outset [21, 22, 23]. No previous studies have examined the effect of carmustine wafers in a treatment programme consisting of 5-ALA guided resection followed by a temozolomide-based chemoradiation: the present findings suggest there is no clinically or statistically significant benefit. In the period since the cohort in this study were treated we have not used carmustine wafers at primary resection of grade IV glioma.

Post-hoc analyses of several trial and data from many retrospective studies support the crucial value of surgical resection and debate the optimal volume of tumour to be removed [24]. Three Cochrane Reviews together with systematic reviews by the European Society for Medical Oncology (ESMO) and the European Association of Neuro-Oncology (EANO) highlight the importance of surgery [2, 3, 25, 26, 27]. More recently, compelling prospective data has begun to emerge showing that complete resection confers a survival advantage, although formal prospective data is lacking. A meta-analysis of three randomized phase III trials that recruited a total of 1056 patients concluded, “complete resection appears to improve survival and may increase the efficacy of adjunct/adjuvant therapies” [28]. A prospective clinical trial of 60 grade IV glioma patients showed lack of efficacy of enzastaurin (a PKC and PI-3 kinase/Akt inhibitor) but a secondary analysis revealed a strong prognostic influence of resection on overall survival [29]. A prospective surgical cohort study of 143 grade IV glioma patients showed that the best clinical outcomes were described in those who had complete resection of enhancing disease (median survival for those without residual disease exceeded 24 months, was 16.9 months for those with residual tumour diameter > 0 to ≤ 1 and 13.9 months for those with > 1.5 cm residual disease) and concluded that completeness of resection acts synergistically with radiochemotherapy [4]. A prospective multicenter study of 345 grade IV glioma patients identified GTR as a prognostic factor in multivariate analysis (HR = 0,60; P = 0.003) for overall survival with those undergoing incomplete resection doing no better than those receiving biopsy only [5]. Finally, a retrospective review of 692 patients in the AVAglio trial reported “post-surgical residual enhancing tumor volume is prognostic for OS in newly diagnosed grade IV glioma patients” [30]. Residual tumour identified by intraoperative 5-ALA fluorescence has also been shown to be an independent prognostic indicator in patients with no remaining enhancing disease on MRI [21]. Findings in the present study are consistent with these previous reports: both residual fluorescence at completion of surgery and residual enhancing tumour on MRI were independently associated with reduced survival. When adjusted for other factors, evidence of complete resection on early post-operative MRI extended median survival by approximately 3 months.

The impact of residual enhancing tumour on outcome raises the question of whether early reoperation to complete the resection would be beneficial in selected patients. More research is needed to characterise the volume and patterns of residual tumour on MRI to assess the safety of such an approach i.e. differentiating ‘missed’ and resectable tumour from disease infiltrating eloquent brain with high likelihood of causing neurological deficit. Resecting small volumes of residual tumour may be challenging in the early post-operative setting: anatomical landmarks will be distorted and neuronavigation systems may be less accurate due to brain shift. In addition, the lack of concordance between residual 5-ALA fluorescence and residual on MRI in a minority of patients requires further investigation to determine if there is genuinely enhancing tumour that does not take up 5-ALA or fluorescent disease that does not enhance. A multimodal approach using a combination of technologies to guide resection, including 5-ALA and others such as intraoperative MRI, may offer the best prospect of achieving complete tumour resection [22].

The principal limitation of the present study is its retrospective nature. The propensity score matching technique was employed to mitigate, as best as possible, selection bias and adjust for imbalance in baseline and pre-implantation variables. This procedure extracts matched subgroups of patients and provides the best available approximation to the balanced groups that would be expected in a hypothetical randomised controlled trial allocating patients to receive 5-ALA guided resection with or without the addition of carmustine wafers. The study represents a real-life cohort of neuro-oncology patients; patient selection was not limited to those who received chemo-radiotherapy, reflecting that some patients may not be fit enough for further treatment after surgery. In addition, there was incomplete data for molecular characterisation of all patients in the study and the lack of association between MGMT methylation and survival is difficult to interpret. Variability within and between assays, and controversy around promotor methylation and protein expression are well recognised [31]. Several studies have reported a lack of correlation between MGMT promotor methylation status and clinical outcome [32, 33, 34, 35, 36] including a clinical trial [34] and a prospective cohort study [35].



This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

No conflict of interest declared.


  1. 1.
    Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 92(2):241–245CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, on behalf of the ESMO Guideline Working Group (2014) High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93–101CrossRefPubMedGoogle Scholar
  4. 4.
    Stummer W, Meinel T, Ewelt C et al (2012) Prospective cohort study of radiotherapy with concominant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108(1):89–97CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kreth FW, Thon N, Simon M et al (2013) Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 24(12):3117–3123CrossRefPubMedGoogle Scholar
  6. 6.
    Chaichana KL, Zadnik P, Weingart JD et al (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–820CrossRefPubMedGoogle Scholar
  7. 7.
    Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003–1013CrossRefPubMedGoogle Scholar
  8. 8.
    Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid resection of malignant glioma; a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401CrossRefPubMedGoogle Scholar
  9. 9.
    Westphal M, Lamszus K, Hilt D (2003) Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir 88(Suppl):61–67Google Scholar
  10. 10.
    Valtonen S, Timonen U, Toivanen et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41:44–48CrossRefPubMedGoogle Scholar
  11. 11.
    Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafer) in patients with primary malignant glioma. Neuro Oncol 5:79–88CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124–131CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Collins VP, Ichimura K, Di Y et al (2014) Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Acta Neuropathol Commun 2:68CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Quillien V, Lavenu A, Sanson M et al (2014) Oucome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol 116:487–496CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399–424CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41(6):403–419CrossRefPubMedGoogle Scholar
  17. 17.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMedGoogle Scholar
  18. 18.
    Henaine AM, Paubel N, Ducray F et al (2016) Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. J Clin Pharm Ther 41(1):47–53CrossRefPubMedGoogle Scholar
  19. 19.
    Gutenburg A, Lumenta CB, Braunsdorf WE et al (2013) The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 113:163–174CrossRefGoogle Scholar
  20. 20.
    Guilfoyle MR, Weerrakkody RA, Oswal A et al (2001) Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhance clinical care for patients with glioblastoma multiforme. Br J Cancer 104:1810–1815CrossRefGoogle Scholar
  21. 21.
    Aldave G, Tejada S, Pay E et al (2013) Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 72:915–920 (discussion 920–921)CrossRefPubMedGoogle Scholar
  22. 22.
    Coburger J, Hagel V, Wirtz CR, Kronig R (2015) Surgery for glioblastoma: impact of the combined use of 5-aminolevulinic acid and intraoperative MRI on extent of resection and survival. PLoS ONE 10:e0131872CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schatlo B, Fandino J, Smoll NR et al (2015) Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgey. Neuro Oncol 17:1560–1567CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Watts C, Sanai N (2016) Surgical approaches for the gliomas. Hanb Clin Neurol 134:51–69CrossRefGoogle Scholar
  25. 25.
    Barone DG, Lawrie TA, Hart MG (2014) Image guided surgery for the resection of brain tumours. Cochrane Database Syst Rev 1:CD009685Google Scholar
  26. 26.
    Hart MG, Grant R, Rogers G, Somerville M, Stein K (2001) Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294Google Scholar
  27. 27.
    Hart MG, Grant R, Walker M, Dickinson H (2005) Surgical resection and whole brain radiation alone for single brain metastases. Cochrane Database Syst Rev 1:CD003292Google Scholar
  28. 28.
    Stummer W, van den Ben MJ, Westphal M (2011) Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir 153(6):1211–1218CrossRefPubMedGoogle Scholar
  29. 29.
    Wick W, Steinbach JP, Platten M et al (2013) Enzastaurin before and concomitant with radiation therapy followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol 15(10):1405–1412CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ellingtons BM, Garcia J, Revil C et al (2016) Residual tumor volume and change in tumor volume durine adjuvant therapy to predict long-term survival in AVAgli: phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo. J Clin Oncol 34(ASCO suppl):abstr 2021Google Scholar
  31. 31.
    Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine. Nat Rev Neurol 6(1):39–51CrossRefPubMedGoogle Scholar
  32. 32.
    Tang K, Jin Q, Yan W et al (2012) Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol 29(2):1292–1296CrossRefPubMedGoogle Scholar
  33. 33.
    Costa BM, Caerio C, Guimaraes I, Martinho O et al (2010) Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep 23(6):1655–1662PubMedGoogle Scholar
  34. 34.
    Clarke JL, Iwamoto FM, Sul J et al (2009) Randomised phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27(23):3861–3867CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Alessandris D’, Montano QG, Larocca N, Maira LM, Pallini G R (2014) Prognostic impact of MGMT promoter methylation in glioblastoma—a systematic review. J Cancer Sci Ther 6L:136–141Google Scholar
  36. 36.
    Stummer W, Reulen HJ, Meinel T et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • William Sage
    • 1
  • Mathew Guilfoyle
    • 1
  • Catriona Luney
    • 1
  • Adam Young
    • 1
  • Rohitashwa Sinha
    • 1
  • Donatella Sgubin
    • 2
  • Joseph H. McAbee
    • 3
  • Ruichong Ma
    • 4
  • Sarah Jefferies
    • 5
  • Rajesh Jena
    • 5
  • Fiona Harris
    • 5
  • Kieren Allinson
    • 6
  • Tomasz Matys
    • 7
  • Wendi Qian
    • 8
  • Thomas Santarius
    • 1
  • Stephen Price
    • 1
  • Colin Watts
    • 1
    • 9
    Email author
  1. 1.Division of Neurosurgery, Addenbrookes HospitalCambridge University NHS Foundation TrustCambridgeUK
  2. 2.Division of NeurosurgeryAzienda Ospedaliera Nazionale SS, Antonio e Biagio e Cesare ArrigoAlessandriaItaly
  3. 3.Department of Clinical Neurosciences, John van Geest Centre for Brain RepairUniversity of CambridgeCambridgeUK
  4. 4.Department of NeurosurgeryJohn Radcliffe Hospital NHS Foundation TrustOxfordUK
  5. 5.Department of Oncology, Addenbrookes HospitalCambridge University NHS Foundation TrustCambridgeUK
  6. 6.Department of Histopathology, Addenbrookes HospitalCambridge University NHS Foundation TrustCambridgeUK
  7. 7.Department of Radiology, Addenbrookes HospitalCambridge University NHS Foundation TrustCambridgeUK
  8. 8.Cambridge Cancer Trial Centre, Cambridge Clinical Trials Unit – Cancer ThemeCambridge University NHS Foundation TrustCambridgeUK
  9. 9.Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrookes HospitalUniversity of CambridgeCambridgeUK

Personalised recommendations